<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The clinical relevance of the interaction between human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and neutrophils has recently begun to emerge </plain></SENT>
<SENT sid="1" pm="."><plain>This review will focus on recently published articles regarding immunomonitoring of neutrophils in blood and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue in clinical trials comprising the main human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types, with a strong emphasis on independent prognostic relevance assessed by multivariate analyses </plain></SENT>
<SENT sid="2" pm="."><plain>The prognostic role of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-infiltrating neutrophils, elevated blood neutrophils and elevated blood neutrophil/lymphocyte ratio has been associated with poor clinical outcome in several human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, most notably in <z:hpo ids='HP_0005584'>renal cell carcinoma</z:hpo>, <z:hpo ids='HP_0002861'>melanoma</z:hpo>, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo>, <z:mpath ids='MPATH_354'>cholangiocarcinoma</z:mpath>, <z:hpo ids='HP_0100843'>glioblastoma</z:hpo>, <z:hpo ids='HP_0100723'>GIST</z:hpo>, gastric, esophageal, lung, ovarian and <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>A striking finding is the notion that high baseline neutrophil count in either <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> or blood, or both, was identified as strong, independent risk factor for poor outcome in multivariate analyses, and the negative prognostic impact of neutrophils was not eliminated by increasing the dose of cytokines, chemotherapy, or targeted therapy </plain></SENT>
<SENT sid="4" pm="."><plain>For several <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, patients benefit most from therapy if baseline neutrophil was low </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, baseline neutrophils over-ride nadir counts in prognostic significance </plain></SENT>
<SENT sid="6" pm="."><plain>In summary, a proportion of patients who do not experience benefit from surgery or medical intervention may be associated with a worst prognosis because they are characterized by baseline <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-related <z:mp ids='MP_0000219'>neutrophilia</z:mp> protecting them from benefit from therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Further research to unraveling the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> biology and new treatment options is encouraged </plain></SENT>
</text></document>